221 filings
Page 4 of 12
S-3/A
3exdnya
5 Aug 21
Shelf registration (amended)
4:48pm
8-K
s6x85
5 Aug 21
Athenex Provides Second Quarter 2021 Corporate and Financial Update
7:50am
CORRESP
1sz5ybocs ww9b
5 Aug 21
Correspondence with SEC
12:00am
UPLOAD
a1wnvk0scc6 keo67w
30 Jul 21
Letter from SEC
12:00am
S-8
8fp3ja 2lo8uyed49o
27 Jul 21
Registration of securities for employees
4:44pm
S-3
t2r46j33y
27 Jul 21
Shelf registration
12:00am
8-K/A
dfzgxvpb r1umqh70y9
20 Jul 21
Financial Statements and Exhibits
4:29pm
8-K
mroqr3o6 tk9y
23 Jun 21
Departure of Directors or Certain Officers
4:05pm
8-K
cszpa 6su61k
6 May 21
Athenex Provides First Quarter 2021 Corporate and Financial Update
7:16am
8-K
26wnn
5 May 21
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
12:00am
8-K
vc8ita5f g7isf28tqp
1 Mar 21
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
7:30am
8-K
52in ce74klud53i3xl
18 Feb 21
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
9:30am
8-K
6swrhyf
5 Nov 20
FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer
7:30am
8-K
arfrkxp3wyxxuszok2o
10 Sep 20
Athenex, Inc. Announces Proposed Public Offering of Common Stock
5:24pm
424B5
0g7udf qb2dz
10 Sep 20
Prospectus supplement for primary offering
4:06pm